Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Kalvista Pharmaceuticals Inc
KALVCurrent price
12.00 USD
+0.27 USD (+2.30%)
Last closed
11.50 USD
Company
www.kalvista.com
ISIN
US4834971032
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
596 587 200 USD
Yield for 12 month
+4.90 %
1Y
3Y
5Y
10Y
15Y
KALV
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts. Address: 55 Cambridge Parkway, Cambridge, MA, United States, 02142
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
26.33 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-86 167 000 USD
Last Year
-802 000 USD
Current Quarter
–
Last Quarter
–
Key Figures KALV
1 year
3 years
5 years
10 years
EBITDA
-180 520 992 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-58.15 %
PEG Ratio
–
Return On Equity TTM
-150.50 %
Wall Street Target Price
26.33 USD
Revenue TTM
3 824 000 USD
Book Value
2.93 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
30.70 %
Dividend Yield
–
Gross Profit TTM
-81 066 000 USD
Earnings per share
-3.77 USD
Diluted Eps TTM
-3.77 USD
Most Recent Quarter
I 2025
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics KALV
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History KALV
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:14
Payout Ratio
–
Last Split Date
22.11.2016
Stock Valuation KALV
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
76.33
Price Sales TTM
107.42
Enterprise Value EBITDA
-3.53
Price Book MRQ
4.11
Financials KALV
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators KALV
For 52 weeks
7.30 USD
15.50 USD
50 Day MA
11.21 USD
Shares Short Prior Month
5 836 841
200 Day MA
11.07 USD
Short Ratio
9.43
Shares Short
5 855 046
Short Percent
13.30 %
BeatStart